Hosted on MSN1h
Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, has made ...
The Sun22h
Weight loss jabs like Ozempic and Wegovy could be ‘game-changers’ in tackling common cancer, say doctors
FAT jabs such as Ozempic and Wegovy could be “game changers” in tackling bowel cancer within five years, researchers have claimed Evidence has already shown that injections of the weight-loss drugs ...
i on MSN1h
Why weight loss jabs could send more people to hospital
Rising numbers of people are needing hospital treatment for side effects from weight loss injections and it may be affecting ...
US minority veterans face unequal access to Ozempic and Wegovy, study finds
U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...
Hosted on MSN16h
Why you still have to exercise if you’re using weight loss jabs
Online pharmacies are the only way to get weight loss injections for most people, but doctors are concerned some firms do not ...
Novo Nordisk placed on JPM's Catalyst Watch list into headline data
Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.